Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2000

01-03-2000 | ORIGINAL ARTICLE

Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ

Authors: Beth A. Pulaski, Virginia K. Clements, Matthew R. Pipeling, Suzanne Ostrand-Rosenberg

Published in: Cancer Immunology, Immunotherapy | Issue 1/2000

Login to get access
Metadata
Title
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ
Authors
Beth A. Pulaski
Virginia K. Clements
Matthew R. Pipeling
Suzanne Ostrand-Rosenberg
Publication date
01-03-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 1/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050024

Other articles of this Issue 1/2000

Cancer Immunology, Immunotherapy 1/2000 Go to the issue

ORIGINAL ARTICLE

B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells

ORIGINAL ARTICLE

Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4

ORIGINAL ARTICLE

Initial steps in lymph node metastasis formation in an experimental system: possible involvement of recognition by macrophage C-type lectins

ORIGINAL ARTICLE

Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer

ORIGINAL ARTICLE

Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits